222 related articles for article (PubMed ID: 15287917)
1. Initial expression of interferon alpha receptor 2 (IFNAR2) on CD34-positive cells and its down-regulation correlate with clinical response to interferon therapy in chronic myelogenous leukemia.
Ito K; Tanaka H; Ito T; Sultana TA; Kyo T; Imanaka F; Ohmoto Y; Kimura A
Eur J Haematol; 2004 Sep; 73(3):191-205. PubMed ID: 15287917
[TBL] [Abstract][Full Text] [Related]
2. The relative endogenous expression levels of the IFNAR2 isoforms influence the cytostatic and pro-apoptotic effect of IFNalpha on pleomorphic sarcoma cells.
Gazziola C; Cordani N; Carta S; De Lorenzo E; Colombatti A; Perris R
Int J Oncol; 2005 Jan; 26(1):129-40. PubMed ID: 15586233
[TBL] [Abstract][Full Text] [Related]
3. Treatment with IFNalpha in vivo up-regulates serum-soluble TNF-related apoptosis inducing ligand (sTRAIL) levels and TRAIL mRNA expressions in neutrophils in chronic myelogenous leukemia patients.
Tanaka H; Ito T; Kyo T; Kimura A
Eur J Haematol; 2007 May; 78(5):389-98. PubMed ID: 17432976
[TBL] [Abstract][Full Text] [Related]
4. L-selectin expression is low on CD34+ cells from patients with chronic myeloid leukemia and interferon-a up-regulates this expression.
Martín-Henao GA; Quiroga R; Sureda A; González JR; Moreno V; García J
Haematologica; 2000 Feb; 85(2):139-46. PubMed ID: 10681720
[TBL] [Abstract][Full Text] [Related]
5. Evolution of bone marrow fibrosis and stromal antigenic expression in chronic myeloid leukemia on alpha interferon and Ara-C therapy.
Straetmans N; Ma DD; Nevell DF; Arthur C
Hematopathol Mol Hematol; 1996; 10(4):213-22. PubMed ID: 9042664
[TBL] [Abstract][Full Text] [Related]
6. Distinct molecular phenotype of malignant CD34(+) hematopoietic stem and progenitor cells in chronic myelogenous leukemia.
Kronenwett R; Butterweck U; Steidl U; Kliszewski S; Neumann F; Bork S; Blanco ED; Roes N; Gräf T; Brors B; Eils R; Maercker C; Kobbe G; Gattermann N; Haas R
Oncogene; 2005 Aug; 24(34):5313-24. PubMed ID: 15806158
[TBL] [Abstract][Full Text] [Related]
7. Comparable potency of IFNalpha2 and IFNbeta on immediate JAK/STAT activation but differential down-regulation of IFNAR2.
Marijanovic Z; Ragimbeau J; van der Heyden J; Uzé G; Pellegrini S
Biochem J; 2007 Oct; 407(1):141-51. PubMed ID: 17627610
[TBL] [Abstract][Full Text] [Related]
8. Expression of type I interferon receptor as a predictor of clinical response to interferon-alpha therapy of gastrointestinal cancers.
Ota H; Nagano H; Doki Y; Sekimoto M; Kondo M; Wada H; Nakamura M; Noda T; Damdinsuren B; Marubashi S; Miyamoto A; Takeda Y; Dono K; Umeshita K; Nakamori S; Wakasa K; Sakon M; Monden M
Oncol Rep; 2006 Aug; 16(2):249-55. PubMed ID: 16820899
[TBL] [Abstract][Full Text] [Related]
9. Modulation of IFNAR1 mRNA expression in multiple sclerosis patients.
Serana F; Sottini A; Ghidini C; Zanotti C; Capra R; Cordioli C; Caimi L; Imberti L
J Neuroimmunol; 2008 Jun; 197(1):54-62. PubMed ID: 18482773
[TBL] [Abstract][Full Text] [Related]
10. Interferon receptor expression in multiple sclerosis patients.
Oliver B; Mayorga C; Fernández V; Leyva L; León A; Luque G; López JC; Tamayo JA; Pinto-Medel MJ; de Ramon E; Blanco E; Alonso A; Fernández O
J Neuroimmunol; 2007 Feb; 183(1-2):225-31. PubMed ID: 17188754
[TBL] [Abstract][Full Text] [Related]
11. Upregulation of interferon-alpha receptor expression in hydroxyurea-treated leukemia cell lines.
Tamura T; Matsuzaki M; Harada H; Ogawa K; Mohri H; Okubo T
J Investig Med; 1997 Apr; 45(4):160-7. PubMed ID: 9154296
[TBL] [Abstract][Full Text] [Related]
12. IFNAR1 and IFNAR2 polymorphisms confer susceptibility to multiple sclerosis but not to interferon-beta treatment response.
Leyva L; Fernández O; Fedetz M; Blanco E; Fernández VE; Oliver B; León A; Pinto-Medel MJ; Mayorga C; Guerrero M; Luque G; Alcina A; Matesanz F
J Neuroimmunol; 2005 Jun; 163(1-2):165-71. PubMed ID: 15885318
[TBL] [Abstract][Full Text] [Related]
13. Immune-mediated complications during interferon alpha therapy in chronic myelogenous leukemia.
Tóthová E; Kafková A; Stecová N; Fricová M; Guman T; Svorcová E
Neoplasma; 2002; 49(2):91-4. PubMed ID: 12088112
[TBL] [Abstract][Full Text] [Related]
14. Intracellular cytokine analysis of interferon-gamma in T cells of patients with chronic myeloid leukemia.
Aswald JM; Lipton JH; Messner HA
Cytokines Cell Mol Ther; 2002 Dec; 7(2):75-82. PubMed ID: 12607798
[TBL] [Abstract][Full Text] [Related]
15. Severe functional alterations in vitro in CD34(+) cell subpopulations from patients with chronic myeloid leukemia.
Chávez-González A; Rosas-Cabral A; Vela-Ojeda J; González JC; Mayani H
Leuk Res; 2004 Jun; 28(6):639-47. PubMed ID: 15120942
[TBL] [Abstract][Full Text] [Related]
16. Impact of BCR/ABL gene expression on the proliferative rate of different subpopulations of haematopoietic cells in chronic myeloid leukaemia.
Primo D; Flores J; Quijano S; Sanchez ML; Sarasquete ME; del Pino-Montes J; Gaarder PI; Gonzalez M; Orfao A
Br J Haematol; 2006 Oct; 135(1):43-51. PubMed ID: 16939497
[TBL] [Abstract][Full Text] [Related]
17. Prolonged chronic phase in chronic myelogenous leukemia after homoharringtonine therapy.
Li YF; Deng ZK; Xuan HB; Zhu JB; Ding BH; Liu XN; Chen BA
Chin Med J (Engl); 2009 Jun; 122(12):1413-7. PubMed ID: 19567163
[TBL] [Abstract][Full Text] [Related]
18. Philadelphia chromosome-positive chronic myelogenous leukemia: functional defects in circulating mature neutrophils of untreated and interferon-alpha-treated patients.
Kasimir-Bauer S; Ottinger H; Brittinger G; König W
Exp Hematol; 1994 May; 22(5):426-31. PubMed ID: 8174673
[TBL] [Abstract][Full Text] [Related]
19. Interferon-alfa for chronic myeloid leukemia.
Baccarani M; Russo D; Rosti G; Martinelli G
Semin Hematol; 2003 Jan; 40(1):22-33. PubMed ID: 12563609
[TBL] [Abstract][Full Text] [Related]
20. Effect of interferon-alpha on chromosome abnormalities in treated chronic myelogenous leukemia patients.
Tanaka H; Tanaka K; Oguma N; Ito K; Ito T; Kyo T; Dohy H; Kimura A
Cancer Genet Cytogenet; 2004 Sep; 153(2):133-43. PubMed ID: 15350303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
